The EGFR-targeting antibody cetuximab is also used under the prerequisite of wildtype KRAS or BRAF status, as mutations in these oncogenes render tumours insensitive to EGFR-targeted therapy9,11,12. This evidence concerns the gene KRAS and neoplasm.